Drägerwerk stock (DE0005550636): 5-year investment returns +20.7% as of May 2026

Drägerwerk shares have delivered a 20.7% return for investors holding since May 2021, with the stock rising from 74.40 EUR to 89.80 EUR on XETRA. Market cap stands at 1.49 billion EUR amid medical tech positioning.

Drägerwerk AG & Co. KGaA shares showed solid long-term performance, with a hypothetical 10,000 EUR investment from five years ago now worth 12,069.89 EUR, reflecting a 20.7% gain as of May 8, 2026. The stock closed at 89.80 EUR on XETRA, up from 74.40 EUR on May 11, 2021, according to finanzen.at as of 05/08/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Drägerwerk AG & Co. KGaA
• Sector/industry: Medical and safety technology
• Headquarters/country: Germany
• Core markets: Healthcare, safety equipment globally
• Key revenue drivers: Medical devices, gas detection
• Home exchange/listing venue: XETRA (DRW3)
• Trading currency: EUR

Drägerwerk AG & Co. KGaA: core business model

Drägerwerk AG & Co. KGaA develops, produces, and markets medical and safety technology products worldwide. The company operates in two main segments: medical technology for ventilation and patient monitoring, and safety technology including gas detection and personal protective equipment. This dual focus positions Drägerwerk in critical areas like hospitals and industrial safety, with products used in over 190 countries, according to its investor relations page as of 05/11/2026.

Revenue stems primarily from recurring sales of consumables and services alongside equipment. The medical division benefits from demand in intensive care units, while safety products serve firefighting, mining, and chemical industries. Drägerwerk's innovation in areas like breathalyzers enhances its role in regulatory compliance markets.

Main revenue and product drivers for Drägerwerk AG & Co. KGaA

Key drivers include ventilators, anesthesia systems, and phototherapy equipment, where Drägerwerk ranks among top global players. A MarketsandMarkets report projects the phototherapy market to reach $0.62 billion by 2031, listing Drägerwerk alongside GE HealthCare and others as of 05/2026. Safety products like alcohol testers contribute to steady demand from law enforcement and workplaces.

Drägerwerk's exposure to US markets comes via sales to hospitals and safety sectors, aligning with American healthcare spending trends. The TecDAX-listed stock reflects its mid-cap status in Germany's tech-health space.

Industry trends and competitive position

The medical device sector sees growth from aging populations and post-pandemic ICU expansions, benefiting Drägerwerk's portfolio. Competitors include GE HealthCare in the US, but Drägerwerk's safety tech niche provides diversification. Breathalyzer innovations, as noted in industry coverage, underscore its safety leadership as of recent.

Why Drägerwerk AG & Co. KGaA matters for US investors

US investors track Drägerwerk for its ADRs potential and exposure to global medtech, with products integrated into American hospitals and OSHA-compliant safety gear. The 20.7% five-year return highlights resilience amid Eurozone volatility, offering diversification from pure US plays.

Conclusion

Drägerwerk AG & Co. KGaA demonstrates steady performance with a 20.7% five-year gain and positioning in growing medtech segments like phototherapy. Its dual medical-safety focus supports relevance for US portfolios seeking international exposure. Investors monitor upcoming earnings and market trends for continued insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.